Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Ocular Therapeutix Stock Tumbles After Eye Study Failure

Published 23/10/2021, 02:56 am
Updated 23/10/2021, 02:56 am
© Reuters.

© Reuters.

By Sam Boughedda 

Investing.com — Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) tumbled over 34% Friday after the failure of its Phase 2 clinical trial of OTX-CSI to treat dry eye disease.

Ocular Therapeutix shares are trading around the $7.09 mark, its lowest level in over a year. 

The Massachusetts-based company said the trial did not meet its primary endpoint of increased tear production at 12 weeks as measured by the Schirmer's Test. 

The goal of the Phase 2 U.S.-based clinical trial of OTX-CSI was to assess the safety, tolerability, durability, and efficacy of two different formulations of OTX-CSI by measuring signs and symptoms of dry eye disease in 140 subjects treated in both eyes over 16 weeks.

"While we are disappointed by these results, demonstrating clinical benefit in patients with dry eye disease remains a significant unmet need and we will continue to review the data for additional information that may inform future development of this program," said Antony Mattessich, president and CEO of Ocular Therapeutix.

"We remain confident in the potential of our hydrogel-based formulation technology and its ability to deliver innovative ophthalmology therapies," he added. 

H.C. Wainwright analyst Yi Chen recently increased Ocular Therapeutix's price target to $18 from $17, reiterating a buy rating after the FDA approved Dextenza to treat ocular itching.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.